Project Grant R50CA293840
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$104K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This Project Grant award, funded by the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research on using cell-free DNA fragmentomics as prognostic and treatment resistance biomarkers in metastatic castration-resistant prostate cancer (mCRPC). The $680,453 award to the University of Wisconsin System will investigate three key aims: 1) determining if baseline circulating tumor DNA (ctDNA) fragmentomics scores are prognostic biomarkers in...
This $649,486 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cedars-Sinai Medical Center aims to develop an innovative, minimally invasive liquid biopsy assay that can identify molecular subtypes of lethal prostate cancer. The key objectives are to: Perform analytical validation of technologies for isolating large oncosomes (LO) from patient plasma samples for clinical use. Develop a multianalyte LO-based assay to detect lethal...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $538,553.00 to the University of Miami to conduct longitudinal imaging and liquid biopsy studies to identify markers for prostate cancer radiotherapy outcomes. The goal is to develop a multivariable model that incorporates pre-treatment and longitudinal multiparametric MRI features and circulating tumor cells to guide physicians' decisions on radiation therapy...
The National Cancer Institute (NCI) awarded a $287,300 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of California, Los Angeles (UCLA) to conduct research aimed at improving prostate cancer risk stratification and clinical management. The key objectives are to investigate whether DNA damage repair gene variants, prostate cancer polygenic risk, and genetic ancestry can help predict: 1) progression from active surveillance, and 2) biochemical relapse after therapy. The...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) will provide $139,184 to the Fred Hutchinson Cancer Center in Seattle, WA to support research on the role of RNA components of the translation apparatus in prostate cancer plasticity and therapy response. The key objectives are to: 1) elucidate how a specific tRNA (ARG-TCT-1-1) impacts lineage plasticity in prostate cancer, and 2) determine the mechanisms by which 5' UTR-specific mRNA translation...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the Dana-Farber Cancer Institute, Inc. (DFCI) provides $627,474 to support research aimed at improving the detection, diagnosis, and understanding of prostate cancer progression. The key objectives of this 5-year project are to: 1) Identify clinically relevant epigenomic signatures in liquid biopsies that can detect the emergence of treatment-resistant neuroendocrine...
This $785,833 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports advanced research to target immunotherapy-resistant lesions and eradicate oligometastatic prostate cancer. Awarded to the University of Wisconsin System, the research aims to transform healthcare for military service members and the broader public by investigating innovative approaches to disease prevention, diagnosis,...
This $181,640 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research led by a clinical scientist at The University of Texas MD Anderson Cancer Center. The primary objectives are to: Expand on the role of liquid biopsy biomarkers, specifically circulating tumor DNA (ctDNA) and extravesicle RNA (evRNA), to generate novel combination immunotherapy trials for colorectal and anal cancers. This includes analyzing samples from...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Louisville in the amount of $234,889 to fund research aimed at developing a novel immunotherapy regimen for prostate cancer. The research project, titled "Guadecitabine-Directed Immune Regulation in Targeting Prostate Cancer," seeks to investigate how the epigenetic modulator guadecitabine can enhance antigen presentation and increase prostate...
This Project Grant award of $683,979 from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), supports research by Weill Medical College of Cornell University to investigate the molecular mechanisms underlying prostate cancer progression and therapeutic resistance. The research aims to define how specific genetic alterations, particularly mutations in the SPOP gene, impact prostate cancer cell lineage fidelity and shape the development of...